Remibrutinib oral treatment

Phase 3

Remibrutinib oral treatment is one of 8 therapeutic programs targeting Relapsing Multiple Sclerosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Relapsing Multiple SclerosisRecruiting

Relapsing Multiple SclerosisPhase 3

Recruiting

Competition

Competitive Landscape

8 competitors in Relapsing Multiple Sclerosis

#DrugCompanyPhaseTrials

Ocrevus

Roche

Approved

2 2

Rhapsido

Novartis

Phase 3

2 3

Aubagio

Sanofi

Phase 3

2 4

Fenebrutinib

Roche

Phase 3

2 5

Remibrutinib oral treatment

Novartis

Phase 3

1 6

Gilenya

Novartis

Preclinical

1 7

BRIUMVI

TTG Therapeutics, Inc.

Preclinical

1 8

CABA-201

CCabaletta Bio

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 3Recruiting

Relapsing Multiple Sclerosis

NCT06846281

Clinical

Trials by Indication[1]

Relapsing Multiple Sclerosis1 trial

A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib

Recruiting· Novartis logo

Novartis·Phase 3·NCT06846281·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Remibrutinib oral treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Remibrutinib oral treatment. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novartis

Remibrutinib oral treatment

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Relapsing Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News